1 / 29

OUTCOME OF A NATIONAL COHORT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS

OUTCOME OF A NATIONAL COHORT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS N Gorodnitski, PJ Hashkes, M Mukamel, S Padeh, R Brik, J Barash, D Mevorach, Y Berkun, Z Tauber, J Press, L Harel, P Navon, Y Naparstek, Y Uziel, Pediatric Rheumatology Study Group of Israel. INTRODUCTION.

elton-freeman
Download Presentation

OUTCOME OF A NATIONAL COHORT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OUTCOME OF A NATIONAL COHORT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS N Gorodnitski, PJ Hashkes, M Mukamel, S Padeh, R Brik, J Barash, D Mevorach, Y Berkun, Z Tauber, J Press, L Harel, P Navon, Y Naparstek, Y Uziel, Pediatric Rheumatology Study Group of Israel

  2. INTRODUCTION • The clinical manifestations of childhood SLE • range from mild constitutional symptoms to progressive • involvement of all target organs. • A difference in clinical manifestations are • related to genetic and environmental factors. • We present a large unique national series • of the Israeli SLE children.

  3. OBJECTIVES To describe the clinical manifestations and outcomes of a national Israeli cohort of pediatric patients with systemic lupus erythematosus (SLE).

  4. METHODS • Patients were identified from the Israeli national • registry of children with rheumatic diseases who • were diagnosed and followed between 1987-2003. • A retrospective charts data analysis on all cases • meeting the ACR diagnostic criteria of childhood • onset SLE.

  5. Web site internet access for data entry

  6. ACR Criteria

  7. Laboratory assessment

  8. Growth parameters Therapy

  9. JSLE SLEDAI

  10. Damage Index

  11. METHODS • Descriptive analysis of demographic • initial and anytime clinical manifestations • SLE disease activity index (SLEDAI) • SLE collaborating clinics/ACR (SLICC/ACR) • disease damage scores

  12. RESULTS AT DIAGNOSIS -102 patients 81% females Mean age - 13.3 ± 2.6 years (range 6.9 - 17.7) Median age – 13.4 PRINTO - 557 patients – 39 countries 82% females Median age – 12.2

  13. At Diagnosis Initial clinical manifestations: Hematological - 94% Malar rash - 49% Musculoskeletal (non erosive arthritis)-45% Renal involvement - 41% Oral or nasal ulcerations - 21% Serositis -16%. (pleuritis 13, pericarditis – 6) CNS - 7%

  14. Initial clinical manifestations HSC Canadian study Our Study Hematological - 94% - -- Malar rash - 49% - 68 Musculoskeletal -45% - 61 Renal involvement - 41% - 51 Oral or nasal ulcerations - 21% - 29 Serositis -16%. - 15 CNS - 7% - 15

  15. Clinical manifestations any time At presentation % any time % Hematological - 94% 100 Malar rash - 49% 56 Musculoskeletal -45% 58 Renal involvement - 41% 53 Oral or nasal ulcerations - 21% 26 Serositis -16%. 19 CNS - 7% 8

  16. Renal-41% 27 had biopsies DPGN – 15 MPGN - 4 Mesangial – 5 Focal segmental – 6 Some had more than 1 biopsy Nephrotic syndrome – 2 1 had renal transplant

  17. Hematological - 94% Anemia– 77% Leukopenia < 5000 – 53% Lymphopenia < 1500 – 47% Thrombocytopenia < 150000 - 35% ESR – 70mm/h (PRINTO -57) Mean HgB – 10.9 g/dL (PRINTO -10.9) Mean lymphocyte count - 1450

  18. CNS - 7% Psychosis –3 Seizures –4 Pseudotumor - 3 Ataxia – cerebelitis – 3 Chorea – 1 TIA – 2 Brain infarction - 1 CT – 5 patients – 1 infarction, EEG – 1 slow activity

  19. At Diagnosis Mean SLEDAI -17.2 ± 9.0 (range 2 - 60). Median - 17 TREATMENT - 80 children (80%) started therapy with corticosteroids, 19 (19%) with immunosuppressive drugs. PRINTO – Median SLEDAI - 17

  20. 1 YEARS FOLLOW UP -83 children Mean SLEDAI of 8.2 ± 8.0 (range 0 - 46). TREATMENT- 55 (66%) were still on corticosteroids 27 (32%) were on immunosuppressive drugs

  21. 3 YEARS FOLLOW UP - 60 children Mean SLEDAI of 9.5 ± 7.3 (range 0 - 36). TREATMENT - 44 (73%)were on corticosteroids 23 (38%) were on immunosuppressive drugs. Mean SLICC/ACR damage index was 0.4 ± 1.1 (0 - 7). HSC – 1.76 (3.3 years)

  22. 5 YEAR FOLLOW UP -44 children Mean SLEDAI of 6.7 ± 5.2 (0 - 21). TREATMENT - 28 (64%) of them were on steroids 22 (50%) on immunosuppressive drugs. Mean SLICC/ACR damage index was 0.5 ± 1.2 (0 - 7). Death - 1 Chronic Renal Failure – 5

  23. SUMMARY Major organ involvement Renal -53% Serositis -19%. CNS - 8% Malar rash, arthritis – most common signs Laboratory – hematological most common

  24. CONCLUSIONS The 5-year outcome of our national pediatric SLE cohort was in general good, with a progressive decrease in the disease activity (SLEDAI) score. Damage index was very low after 5 years. It is possible that relatively early and prolonged use of immunosuppressive medications in many patients led to the good outcome. Mean SLICC/ACR was 0.4 ± 1.1 (0 - 7). HSC – 1.76 (3.3 years)  (Cumulative disease activity over time – the single most predictor of damage. Immunosuppressive was protective - A@R 2002)

  25. FUTURE ONGOING STUDY • Comparison between adult and pediatric • SLE manifestations • SLERI data (represent whole country) vs. • pediatric national data • Canadian – cSLE more active than aSLE • cSLE – more aggressive therapy (more treatment • complications) • Same disease organ outcome In Israel? Next HIPAK meeting

  26. FUTURE STUDY • Are difference in clinical manifestations related to genetic and environmental factors? • SLERI project – DNA for genetic • Looking for risk factors for worse outcome

  27. SLE- acknowledgements • Moshe Rubinstein – website Data collection and analysis • Pediatric rheumatology study group of Israel • SLERI

  28. Thank You!

More Related